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Available online 3 February 2012Antibodies directed against the post-synaptic neuromuscular junction protein, muscle speciﬁc kinase (MuSK)
are found in a small proportion of generalized myasthenia gravis (MuSK-MG) patients. MuSK is a receptor
tyrosine kinase which is essential for clustering of the acetylcholine receptors (AChRs) at the neuromuscular
junction, but the mechanisms by which MuSK antibodies (MuSK-Abs) affect neuromuscular transmission are
not clear. Experimental models of MuSK-MG have been described but there have been no detailed electro-
physiological studies and no comparisons between the MuSK-MG and the typical form with AChR-Abs
(AChR-MG). Here we studied the electrophysiology of neuromuscular transmission after immunization
against MuSK compared with immunization against AChR, and also after passive transfer of IgG from
MuSK-MG or AChR-MG patients. Overt clinical weakness was observed in 6/10 MuSK-immunized and 3/9
AChR-immunized mice but not in those injected with patients' IgG. Miniature endplate potentials (MEPPS)
were reduced in all weak mice consistent with the reduction in postsynaptic AChRs that was found. However,
whereas there was an increase in the quantal release of acetylcholine (ACh) in the weak AChR-immunized
mice, no such increase was found in the weak MuSK-immunized mice. Similar trends were found after the
passive transfer of puriﬁed IgG antibodies from MuSK-MG or AChR-MG patients. Preliminary results showed
that MuSK expression was considerably higher at the neuromuscular junctions of the masseter (facial) than
in the gastrocnemius (leg) with no reduction in MuSK immunostaining at the neuromuscular junctions.
Overall, these results suggest that MuSK antibodies act in at least two ways. Firstly by indirectly affecting
MuSK's ability to maintain the high density of AChRs and secondly by interfering with a compensatory pre-
synaptic mechanism that regulates quantal release and helps to preserve neuromuscular function. These re-
sults raise questions about how MuSK is involved in retrograde signaling, and the combination of post-
synaptic defects with lack of presynaptic compensation may begin to explain the more severe disease in
MuSK-MG patients.
© 2012 Elsevier Inc. Open access under CC BY-NC-ND license.Introduction
Myasthenia Gravis (MG) is an autoimmune disorder affecting the
neuromuscular junction (NMJ). It is characterized by fatigable muscle
weakness resulting from failure of neuromuscular transmission.
Serum antibodies directed against the AChR are found in approxi-
mately 80% of generalized MG cases (AChR-MG). These antibodies
are typically of the complement ﬁxing subclasses IgG1 and IgG3
(Vincent and Newsom-Davis, 1982) (Leite et al., 2008; Rodgaard et
al., 1987). In animal models, active immunization with puriﬁed
AChR (Patrick and Lindstrom, 1973) and passive transfer with
AChR-MG IgG (Toyka et al., 1975) result in impaired neurotransmis-
sion, conﬁrming that the antibodies are pathogenic. Their primaryClinical Neurosciences, John
Vincent).
NC-ND license.mechanism of action is through loss of the postsynaptic AChR via
complement mediated destruction (Engel et al., 1977), and increased
internalization and degradation of the AChR (Drachman et al., 1978).
Direct pharmacological block of function can occur (Burges et al.,
1990) but is probably uncommon.
A variable proportion of the remaining 20% of MG patients has an-
tibodies to muscle speciﬁc kinase (MuSK-MG) (Hoch, 2003; Hoch et
al., 2001). MuSK is also a postsynaptic protein and belongs to the re-
ceptor tyrosine kinase family. It is critical for the clustering of AChRs
on the postsynaptic membrane during development (DeChiara et
al., 1996) and for ongoing maintenance of the adult neuromuscular
junction (Kong et al., 2004). Compared with AChR-MG, MuSK-MG
more often involves bulbar, facial and respiratory muscles and can
be severe and treatment-resistant (Evoli et al., 2003; Farrugia et al.,
2006). MuSK-Abs are predominantly of the non-complement ﬁxing
IgG4 subclass (McConville et al., 2004), although they can still acti-
vate complement in vitro as some IgG1 is present (Leite et al., 2008).
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on AChR clustering on mouse myotubes (Hoch et al., 2001; Jha et al.,
2006; Shigemoto et al., 2006) as well as reports of effects of active im-
munization against puriﬁed MuSK (Jha et al., 2006; Shigemoto et al.,
2006) and passive transfer of MuSK-MG IgG (Cole et al., 2008; Cole
et al., 2010) to experimental animals. These studies emphasized the
clinical and morphological effects of the antibodies but did not inves-
tigate in detail the underlying neurophysiology or explain why
MuSK-MG is more severe than AChR-MG. Nor is it clear whether ac-
tive immunization against MuSK induces the same changes as passive
transfer of patient's IgG. Here we compared serological and electro-
physiological studies on mice with actively-induced MuSK-MG and
AChR-MG, and compared with the effects of injection of patients'
MuSK or AChR antibodies.
Methods
Puriﬁcation of recombinant MuSK and Torpedo AChR
The DNA for the extracellular domain of human MuSK (residues 21–
465) was ampliﬁed by PCR using the primers 5′-AGTCAGATCTGA-
GAAACTTCCAAAAGCT CCTGTC and 5′-GCATACCGGTATGTGGCAGTCTGG-
CACAGGCCGT. This was sub-cloned into the vector pMT/BiP/V5-HisA.
Drosophilia S2 cells were maintained in Schneider's Drosophila-S2
media (Invitrogen, USA) supplemented with 2 mM glutamine, penicil-
lin/streptomycin/amphotericin B (100 units/ml) and 10% fetal bovine
serum at 28 °C. A stable line expressingMuSK (E22-H452)was generated
by cotransfection of the cloned extracellularMuSK in pMT/BIP-MuSK and
pCoblast using standard calcium phosphate transfection. These trans-
fected S2 cells were grown in selective growthmedia containing Blastoci-
din (25 μg/ml). Protein expression was induced with 500 μM copper
sulfate for 5 days. The presence of a histidine tag on the recombinant
MuSK allowed puriﬁcation on a 7 ml Ni-NTA column. 10 mM Imidaz-
ole was also added to the supernatant before loading onto the col-
umn. This column was washed with equilibration buffer (50 mM
Tris, 500 mM NaCl, 10 mM Imidazole, pH 7.0). Following further
washes with equilibration buffer, the recombinant MuSK was eluted
with 250 mM Imidazole. This was dialyzed against phosphate buff-
ered saline (PBS) overnight before determining the concentration
by spectrometry. The purity of MuSK was checked by SDS/PAGE
and western blotting with MuSK-Ab positive MG sera and commer-
cial anti-MuSK antibodies (R&D, UK). Torpedo AChR was puriﬁed
by afﬁnity chromatography as previously described (Jermy et al.,
1993).
IgG puriﬁcation
IgG was puriﬁed from plasma of MuSK-MG, AChR-MG patients
and healthy individuals on a Protein G-Sepharose fast ﬂow (Sigma,
UK) column. The plasma was ﬁrst centrifuged for ﬁve minutes, dilut-
ed 1:1 with PBS solution and passed through the Protein-G column.
The IgG was eluted with 0.1 M glycine solution (pH 2.3) and neutral-
ized immediately with 1 M Tris pH 8. The protein content of the elut-
ed fractions was measured using a Coomassie Plus assay kit (Pierce,
USA), and the peak fractions pooled and dialyzed against Hartmann's
physiological solution for thirty six hours with three changes. The IgG
was concentrated using polyethelene glycol 6000 (Sigma, UK) and
the concentration determined by spectrometry.
Immunizations
Active immunizations were undertaken on groups of ten eight
week-old female C57BL/6 mice and carried out in accordance with
UK Home Ofﬁce guidelines. Recombinant human MuSK (30 μg), Tor-
pedo AChR (20 μg) and PBS were emulsiﬁed 1:1 with complete
Freund's adjuvant (Sigma, UK). A total of 200 μl of emulsion wasinjected into the base of the tail at day 0. Boosts in Freund's incom-
plete adjuvant were given at days 28 and 56. The mice were bled at
days 40 and 80, and serum prepared and stored at −20 °C. The
mice were observed daily and weighed twice weekly.
For passive transfer 12 female C57BL/6 mice, aged 8 weeks, were
injected intraperitoneally with 50 mg of each puriﬁed IgG daily for
ﬁve days. They were weighed daily and assessed for motor functions
(see below). At termination of all immunizations, blood was taken for
serology and muscles were removed for electrophysiology and other
studies.
Motor function
Mice were tested before each immunization and two weeks after
the last injection by a blinded observer. Prolonged strength was test-
ed using an inverted screen (Cossins et al., 2004) with a maximum
time limit of 600 s. If the mice fell off before 600 s, they were retested.
The average time they were able to maintain their grip is shown. To
assess their bulbar function, the mice were partially starved over-
night, and then given condensed milk diluted 1:1 with water (total
2 ml placed in a container on the ﬂoor of the test cage). The total vol-
ume consumed in the 90 s after drinking commenced was recorded.
Antibody assays
For the radio-immunoprecipitation assays, 2.5 μl mouse or human
serum was made up to 25 μl with PTX buffer (0.02 M phosphate, 0.1%
Triton X-100 pH 7.2). These were serially diluted ﬁvefold, added to
25 μl 125I recombinant human MuSK (RSR, UK) and left overnight at
4 °C. 25 μl anti-human IgG (RSR, UK) was added with appropriate
amounts of normal human or mouse serum to ensure comparable
IgG levels and left for 90 min. A further 0.5 ml PTX buffer was then
added, samples microfuged at 13,000 rpm, washed and counted on
an automated gamma counter (Packard, Meriden). Cell-based assays
looking for IgG and C3b binding were performed and analyzed as pre-
viously described (Leite et al., 2008) with the exception that mouse
serum was diluted 1:100 for initial assays, or by serial titrations for
accurate levels.
Ex-vivo electrophysiology
Phrenic nerve/hemidiaphragm preparations were placed in Krebs'
solution (118 mM NaCl, 4.7 mM KCl, 1.2 mM MgSO4·7H2O, 1.2 mM
KH2PO4, 24.9 mM NaHCO3, 11.1 mM D-glucose and 2.5 mM CaCl2
pH7.4), before determining miniature endplate potentials (MEPPs),
endplate potentials (EPPs) and quantal contents (QC) as previously
described (Cossins et al., 2004).
Recordings, from at least ten endplates from one hemidiaphragm
of each animal, were accumulated over a 90 minute period at room
temperature. Analysis was performed using pClampﬁt 9 software
(Axon laboratory, CA, USA) and for each endplate, a minimum of 20
MEPPs and EPPs were required to generate a mean value. All MEPPs
and EPPs were standardized to a resting membrane potential of
−80 mV. Mean quantal content (m) was calculated by the direct
method using the formula described elsewhere (Wood and Slater,
2001).
AChR quantiﬁcation
Quantiﬁcation of endplate AChR was undertaken as previously de-
scribed (Cossins et al., 2004; Jermy et al., 1993). The unused hemi-
diaphragm was incubated for 2 h in Krebs' solution containing an
excess of 125I-α-bungarotoxin. It was then washed and left overnight
in Krebs' solution. The following day it was ﬁxed in 2.5% glutaralde-
hyde in 80% Krebs' solution for two hours at room temperature before
being washed in distilled water. The diaphragms were stained for
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weighed, measured and the cpm bound to the endplate regions
counted on a gamma counter. The cpm of a similar weight of non-
endplate containing muscle was subtracted and speciﬁc endplate
binding calculated as cpm/mg/cm.
MuSK staining and quantiﬁcation
Masseter and gastrocnemius muscles were dissected and placed in
Cryotekmolds containing 15% gelatin and 25% Tissue Tek/OCT (Sakura
Finetek, Japan) and allowed to set at 4 °C, frozen in isopentane cooled
in liquid nitrogen, and stored at−80 °C. Muscle sections (10–15 μm)
were cut using a Leica CM1900 cryostat at−18 °C and mounted on to
polytetraﬂuoroethylene coated slides. The muscle sections were
rinsed with PBS, and blocked with 1% BSA and 10% goat serum in
PBS for 30 min. Rabbit anti-MuSK antibody (83033), a polyclonal anti-
body directed against an extracellular epitope (kindly donated by Dr
Steve Burden, New York), was diluted 1:6000 in the blocking solution
and applied to the sections overnight at 4 °C. After washing, anti-
rabbit IgG Alexa ﬂuor 488 (Invitrogen, Paisley) diluted 1:500 in block-
ing solution was added for 60 min at room temperature. After further
PBS washes, α-bungarotoxin Alexa Fluor 568 diluted 1:5000 in PBS
with 1% BSA was applied for 30 min at room temperature before the
ﬁnal washes. In order to prevent bias, individual endplates were iden-
tiﬁed bymeans of their AChR staining before the corresponding MuSK
imageswere acquired on an Axion 200 inverted Zeiss ﬂuorescencemi-
croscope using Open Lab software with all photographs acquired
under the same conditions. Overall at least six sections were obtained
for eachmousemuscle with aminimum of four photographs per mus-
cle section, each typically containing several endplates. The integrated
intensity of individual endplates was then measured using Meta-
morph software (Universal Imaging Corporation, USA).Fig. 1. Results of active immunization.(a) Body weight (mean+SEM) of AChR, MuSK and
boosts. Repeated ANOVA and Bonferroni post test *pb0.05; ***pb0.001. (b) Examples of a
screen at the end of the study in the three groups and mean+SEMs. At baseline all mice w
screen before 600 s on two consecutive occasions are shown in the boxes. Kruskal–Wallis t
to 125I-recombinant human MuSK (mean+SEM), after subtraction of cpm precipitated by no
ANOVA and Bonferroni post test **pb0.01; ***pb0.001.Statistics
Repeated ANOVA was used to analyze differences in weight be-
tween the different groups of mice over time, and the titrations of
mouse MuSK antibody levels. One-way ANOVA was used to analyze
differences in bulbar function and prolonged strength on the inverted
screen. The electrophysiological parameters, AChR and MuSK quanti-
ﬁcation data were all analyzed by means of one-way ANOVA (Krus-
kal–Wallis test with Dunn's multiple comparison test). The
correlations between MEPP amplitude and AChR numbers were
assessed by linear correlation. Graph Pad Prism was used for all
graphs and analyzes.Results
Preliminary studies of immunization against MuSK
We ﬁrst immunized mice with 30 μg of MuSK or PBS, boosting at
28 and 56 days and terminating at day 70. The mouse sera were pos-
itive for IgG antibodies binding to MuSK expressed on HEK cells, indi-
cating that they recognized extracellular epitopes (Supplementary
Fig. 1a). These antibodies were equally IgG1, IgG2b and IgG2c sub-
types, with little IgG3 or IgM (data not shown). At termination,
there was a signiﬁcant reduction in MEPP and EPP amplitudes (Sup-
plementary Fig. 1b) in MuSK-immunized mice compared with PBS-
immunized mice. MuSK-immunized mice showed loss of AChR stain-
ing at the endplates in both masseter (facial) and gastrocnemius
(limb) muscles but surprisingly no loss of MuSK expression in these
muscles (Supplementary Fig. 1c). Moreover, MuSK expression was
considerably higher in masseter than in gastrocnemius (Supplemen-
tary Fig. 1c).PBS immunized mice following immunization. Arrows show initial immunization and
healthy mouse (above) and a weak mouse (below). (c) Performance on the inverted
ere able to sustain grip for 600 s without falling. Those mice that fell off the inverted
est and Dunn's multiple comparison test * pb0.05. (d) Serial titrations of sera binding
rmal mouse serum. Three weak and three non-weak MuSK-mice were tested. Repeated
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The main study repeated the immunization using 30 μg of MuSK
and compared the results with 20 μg of Torpedo AChR using a similar
protocol to that above but with mice sacriﬁced between 77 and
84 days. Towards the end of the study period, the weights of the
MuSK-immunized mice (MuSK-mice) were signiﬁcantly less than
those of the AChR-immunized (AChR-mice) or PBS control (PBS-
mice) groups (Fig. 1a). Objective weakness was apparent in six of
the ten MuSK-mice and three of the nine AChR-mice (see Fig. 1b for
examples), as demonstrated by a reduction in grip times on the
inverted wire-mesh screen on two consecutive tests (mean value
shown, Fig. 1c). At day 75, we tried to demonstrate bulbar involve-
ment by measuring the amount of condensed milk drunk in 90 s,
but although the results were lower in MuSK- and AChR-mice, partic-
ularly in the weak mice, they were not signiﬁcantly different from the
PBS-mice, largely because of considerable variations and low num-
bers in each group (Supplementary Fig. 2). For the results that follow,
the weak mice will be described separately from those that did not
show any clinical weakness.
Serum levels of MuSK-Abs two weeks after the second boost were
signiﬁcantly higher in the weak MuSK-mice compared with the non-
weak MuSK-mice (Fig. 1d). The mice were sacriﬁced and individual
muscle ﬁbers (minimum ten per mouse) of the phrenic nerve hemi-
diaphragmwere studied with microelectrodes. There were signiﬁcant
reductions in MEPP amplitudes, MEPP frequencies and EPP ampli-
tudes between the ﬁve groups (Figs. 2a–c) with the weak AChR-
and MuSK-mice having the lowest values. The MEPP frequencies
were particularly low in MuSK-MG mice, more than could be
accounted for by loss of MEPP amplitudes in the background (dataFig. 2. Effect of active immunization on electrophysiology of neuromuscular transmission.In
column) examining (a) MEPP amplitude, (b) MEPP frequency, (c) EPP amplitude and (d) qu
multiple comparison test) are shown for each measurement: *pb0.05; **pb0.01; ***pb0.00
MuSK-mice. Analysis performed by linear regression.not shown), and may reﬂect presynaptic changes which have been
reported in MuSK-MG models (e.g. Cole et al., 2008; ter Beek et al.,
2009). The quantal contents were signiﬁcantly raised in the weak
AChR-mice (Fig. 2d) but not in the MuSK-mice. There was an inverse
correlation between quantal content and MEPP amplitude in the
AChR-mice but no such correlation in the MuSK-mice (Figs. 2e,f).
To see whether the reduced MEPP amplitudes were associated
with reduced numbers of AChRs, we used 125I-α-bungarotoxin to
measure the number of endplate AChRs. The numbers of AChRs
were reduced in all four test groups compared to the PBS-mice
(Fig. 3a), particularly the two weak AChR-mice (one hemidiaphragm
was damaged and could not be tested), and overall there was a signif-
icant correlation between mean AChR numbers and the mean MEPP
amplitudes for each animal (Fig. 3b).
Passive transfer
To see if the results of active immunization corresponded to those
that might be found in patients, we used passive transfer with IgG pu-
riﬁed from the plasma exchange samples of two MuSK-MG patients
with high antibody titers, MuSK-MG-A (titer 78.1 nM) and MuSK-
MG-B (titer 74.1 nM), and one AChR-MG patient (see Table 1 for de-
tails). These IgG preparations were chosen partly because they bound
to mouseMuSK or AChR, respectively, and the MuSK IgGs reduced the
clustering of mouse AChRs in C2C12 cells (data not shown).
Preliminary experiments were performed with 10 mg of IgG for
ﬁve days, but there was only a marginal reduction in MEPP ampli-
tudes (data not shown). However, following injection of 50 mg of
IgG daily for ﬁve days, the antibody levels in sera from the MuSK-
MG-A and B injected mice were very similar to those in the plasmadividual data from each muscle ﬁber for each group (number of mice given below each
antal content. Mean+SEM and signiﬁcant differences (Kruskal–Wallis test with Dunn's
1. Correlation between MEPP amplitude and quantal content in (e) AChR-mice and (f)
Fig. 3. Effect of active immunization on AChR numbers.(a) AChR numbers were mea-
sured by 125I-α-bungarotoxin binding to endplate speciﬁc regions of the muscle. The
results are shown as cpm/mg/cm (mean+SEM) bound to endplate-containing muscle
ﬁber bundles (2–3 for each mouse) after subtraction of non-endplate binding. Kruskal–
Wallis test with Dunn's multiple comparison test ***pb0.001. (b) Correlation between
meanMEPP amplitude andmean AChR numbers for each mouse with analysis by linear
regression. Weak mice are shown in the box (b).
Table 1
Patients whose IgG antibodies were used in passive transfer experiments.
AChR-MG
Age at onset 26
Gender M
Symptomatic weakness at presentation Bulbar, facial, limb
Neurophysiology assessment
(muscles tested)
RNS: signiﬁcant decrement (anconeus,
abductor digiti minimi)
Tensilon test Not done
Response to initial plasma exchange Good
Subsequent treatment Cs, Az, IVIG
Clinical course One further relapse required IVIG. Has
remained well on treatment
Thymectomy Good response (pharmacological remission)
Abbreviations:
RNS = repetitive nerve stimulation (at 3 Hz unless stated), SFEMG = single ﬁber elect
corticosteroids, Az = azathioprine, Mx = methotrexate, IST = immunosuppressive therap
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were ﬁve to ten-fold lower than those in the actively immunized mice
(Fig. 1d) and there was no weight loss or overt weakness in any of the
mice. Despite this, a signiﬁcant reduction in MEPP amplitudes was
found in MuSK-MG-A IgG and AChR-MG IgG injected, and to a lesser
extent MuSK-MG-B IgG injected, mice (Fig. 4b). The EPP amplitudes
were also signiﬁcantly reduced but MEPP frequencies were not signif-
icantly altered (data not shown). As with the active immunization in
weak-MuSK-mice, the quantal contents in MuSK-IgG injected mice
were not different from control values, but were reduced compared
with those in mice receiving AChR-MG IgG (Fig. 4c). There was also
a modest reduction in AChR numbers in the MuSK-MG-A injected
mice compared with controls, and a signiﬁcant positive correlation
between MEPP amplitude and AChR numbers in all mice examined
(Figs. 5a,b), but there were no signiﬁcant correlations between quan-
tal contents and MEPP amplitudes (Supplementary data — Fig. 3).Discussion
The results of this study address the electrophysiology of MuSK-
MG and how it differs from AChR-MG. We found that not all MuSK
or AChR immunized mice became weak reﬂecting the greater safety
factor for neurotransmission in mice (Wood and Slater, 2001), but
those that did had markedly reduced MEPP amplitudes, reduced
MEPP frequencies and reduced EPP amplitudes, associated with re-
duced AChR numbers. However, whereas the quantal contents were
raised in weak AChR immunized mice they were normal in weak
MuSK immunized mice. Similar trends were found in mice injected
with two MuSK-MG IgGs, although serum levels of human MuSK an-
tibodies were approximately ﬁve times lower than the mouse MuSK
antibodies in actively immunized mice. Overall we propose that the
weakness seen in both MuSK-immunized and MuSK-MG IgG injected
mice may be due not only to a reduction in postsynaptic AChR num-
bers, with the resulting reduction in MEPP and EPP amplitudes, but
also to a lack of a presynaptic compensatory increase in quantal re-
lease which is seen in AChR-MG. The role of MuSK in the retrograde
signaling that results in these changes needs to be examined further.
It has previously been reported that AChR numbers are not deﬁ-
cient in MuSK-MG (Shiraishi et al., 2005), suggesting that the anti-
bodies must have some indirect effect on neuromuscular
transmission, but these observations were in the limb muscles,
which show less marked clinical and single ﬁber electromyographic
changes (Farrugia et al., 2006); the AChR numbers and morphology
in the more affected patients' muscles were not examined. Although
there have been no systematic electrophysiological studies onMuSK-MG-A MuSK-MG-B
25 6
F F
Ocular, bulbar, facial and respiratory
muscle weakness
Ocular, respiratory and limb
muscle weakness
SFEMG: moderate jitter (abductor
digiti minimi)
RNS: normal (abductor digiti
minimi and abductor pollicis brevis)
Positive Positive
Good Good
PEx, IVIG, Cs, Az IVIG, Cs, Az, Mx
Symptomatic weakness every
9/12 requiring PEx despite long term IST
One further relapse following
cessation of IS treatment. Now on
long term IST
No response Not done
romyography, PEx = plasma exchange, IVIG = intravenous immunoglobulin, Cs =
y.
Fig. 4. Passive transfer of human IgG to mice.(a) Serial titrations of sera binding to 125I-
recombinant human MuSK, after subtraction of cpm precipitated by mouse receiving
normal IgG. Results from individual endplate data (mean+SEM) for each group
(three mice, >10 endplates in each) examining (b) MEPP amplitude and (c) quantal
content. Kruskal–Wallis test with Dunn's multiple comparison test **pb0.01;
***pb0.001.
Fig. 5. Effect of passive transfer on AChR numbers.(a) AChR numbers were measured
by 125I-α-bungarotoxin binding (mean+SEM) to endplate speciﬁc regions of the mus-
cle. Kruskal-Wallis test with Dunn's multiple comparison test * pb0.05. (b) Correlation
between MEPP amplitude and AChR numbers for individual mice with analysis by lin-
ear regression.
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in MEPP frequency and in quantal content in one MuSK-MG intercostal
biopsy compared with those typically found in their AChR-MG patients
(Niks et al., 2011); as here, the reduction in MEPP amplitude was com-
parable in MuSK-MG and AChR-MG biopsies. Their results in that pa-
tient, therefore, were not dissimilar from our ﬁndings in both active
and passive models.
Twomain active immunizationmodels have been described previ-
ously (Jha et al., 2006; Shigemoto et al., 2006), but they focused on
morphological changes rather than the underlying electrophysiology
of neuromuscular transmission. They found fragmentation of AChR
clusters (Jha et al., 2006; Shigemoto et al., 2006) and alterations in
nerve terminal structure and branching (Cole et al., 2008; Jha et al.,
2006) which we saw at some endplates (data not shown). We estab-
lished an active immunization model of MuSK-MG in order tounderstand better the electrophysiology and to compare with immu-
nization against AChR. The MEPP amplitudes are dependent on the
density and number of AChRs, which are typically reduced in MG
(Fambrough et al., 1973; Ito et al., 1978). The reduction in AChR num-
bers in weak MuSK-MGmice is therefore likely responsible for the re-
duced MEPP and EPP amplitudes. There was also a quite marked
reduction in MEPP frequencies; that could have been caused partly
by loss of very small MEPPs in the “noise” of the recordings but, judg-
ing by the frequency distribution of MEPP amplitudes (data not
shown), the proportion of MEPPs that were likely to have been lost
was small (b20%) even in the weak MuSK-mice. The reduced MEPP
frequency would therefore support the existence of some abnormali-
ty of presynaptic function. Of clearer signiﬁcance, there was an in-
crease in the quantal content in the weak AChR-mice that was not
found in the MuSK-mice. A similar increase was previously found in
patients with AChR-MG, and in mice immunized with AChR, and is
thought to represent a presynaptic compensatory mechanism
(Plomp et al., 1995). Our results conﬁrm those ﬁndings in AChR-
mice and support the existence of retrograde signaling from the
post- to pre-synaptic membranes which may be responsible for the
increased quantal release. The mechanism by which this occurs is
not clear, but since the weak MuSK-MG mice did not show the in-
crease in quantal content, MuSK may be involved in this compensato-
ry mechanism, and MuSK antibodies may interfere with this aspect of
MuSK function.
A recent study looked at the bulbar selectivity of MuSK-MG
(Punga et al., 2011). Immunized mice developed marked generalized
muscle weakness and bulbar dysfunction. There was a lower level of
mRNA for MuSK in masseter muscle than in the axial or limb muscles
with upregulation of MuSK mRNA expression after immunization
against MuSK. These results appear to differ from the unexpected
ﬁve-fold greater MuSK protein expression at the neuromuscular
512 S. Viegas et al. / Experimental Neurology 234 (2012) 506–512junctions of masseter compared with gastrocnemius that we found in
preliminary results, and a direct comparison of the protein and mRNA
expression needs to be done.
To our knowledge, this is the ﬁrst attempt to compare the results
of active immunization with passive transfer of human autoanti-
bodies. The results suggest that active immunization provides a useful
model of the human disease, both in the changes observed in MuSK-
MG injected and MuSK-mice and also in the modest but signiﬁcant
differences in the ﬁndings between the MuSK and AChR mice. Al-
though the results were less robust in the MuSK-MG IgG mice, to
those from active immunization, the antibody levels achieved in the
mice sera were lower than those achieved with active immunization.
Previous passive transfer studies have not examined the electrophys-
iology of transmission but have concentrated on morphological
changes that suggest a loss of AChRs and also of a loss of apposition
between pre- and postsynaptic structures after 8 days of injections
(Cole et al., 2008), or the regeneration of neuromuscular junctions
after notexin which was impaired in comparison with control IgG
injected endplates (ter Beek et al., 2009). Studies in patients subse-
quently identiﬁed as being MuSK-Ab positive (AV unpublished data)
also suggested some presynaptic effects in addition to the expected
reduction in MEPP amplitudes (Burges et al., 1994). Overall, results
in both active and passive transfer models of MuSK-MG demonstrate
that there are defects in the function of the presynaptic nerve termi-
nals as well as in the numbers of postsynaptic AChRs, and that these
additional problems may explain some of the disease severity. Since
MuSK is not known to be present in the presynaptic nerve terminal,
further experiments are indicated to explore this potentially impor-
tant aspect of MuSK function.
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